Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
ipo
5
×
national blog main
national top stories
san francisco
5
×
biotech
boston blog main
boston top stories
life sciences
san francisco blog main
san francisco top stories
clinical trials
third rock ventures
warp drive bio
cancer
cancer drugs
deals
medical devices
new york blog main
new york top stories
revolution medicines
san diego blog main
san diego top stories
sanofi
texas
texas blog main
texas top stories
the column group
venture capital
accelerator
accruent
acetylon pharmaceuticals
ai/robotics
alchemy systems
ambys medicines
amgen
andre lacroix
antibiotics
apps
arvinas
astrazeneca
What
ipo
medicines
cancer
make
proteins
research
revolution
way
accruent
acquired
aiming
ambys
austin
based
big
biotech
biotechs
cancer’s
catch
chose
close
company
control
deadly
deal
debuted
despite
device
disease
diseases
diversity
drug
energy
exits
family
firms
formed
frontiers
future
hardest
Language
unset
Current search:
ipo
×
" san francisco "
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
Exits in Austin, Pitch NASA, Diversity in Energy, & More TX Tech
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
